Navigation Links
ASSURE study of experimental agent to raise HDL yields 'disappointing and surprising' results
Date:9/2/2013

AMSTERDAM, The Netherlands, 2 September2013 The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study.

The lack of efficacy of RVX-208 is "disappointing and surprising, given promising earlier findings," noted lead investigator Stephen Nicholls MBBS, PhD, Deputy Director at the South Australian Health and Medical Research Institute, Professor of Cardiology at the University of Adelaide and Consultant Cardiologist at the Royal Adelaide Hospital in Adelaide, Australia.

However, the failure of RVX-208 to incrementally impact atherosclerotic plaque should not be interpreted as a failure of the hypothesis that increasing the level and activity of HDL could result in this benefit, he said.

"RVX-208 represents the first epigenetic foray into the metabolic treatment of cardiovascular disease, and ongoing clinical trials will evaluate the potential cardiovascular efficacy of other agents that target HDL."

ASSURE was a prospective, randomized, double-blind clinical trial carried out at 60 centers.

It randomized 323 patients with low HDL and coronary disease who had a target blood vessel for imaging with less than 50% stenosis.

All patients received treatment with either atorvastatin 10-40 mg daily or rosuvastatin 5-20 mg daily during the study and were also randomized to receive either RVX-208 100 mg (n=244) or placebo (n=80) twice daily for 26 weeks.

The primary and secondary outcomes of the study were change from baseline in percent atheroma volume (PAV) and normalized total atheroma (TAV), both measures of the amount of plaque present in the coronary artery.

Intravascular ultrasonography was used at baseline and the end of the study to measure these outcomes.

Of the 281 patient
'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
44-754-070-4494
European Society of Cardiology
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Assure A Smile Promotes Oral Health Awareness in Miami with New Website
2. New Christie Assure Program Revolutionizes VeinViewer Utilization Services at Hospitals Across America
3. Tinnitus Relief and Better Hearing Assured by an All-New Product
4. Medical Cost Trends Likely to Reaccelerate According to Assured Research
5. Study Suggests Vaccine May Help Kids With Brain Cancer
6. Study reveals how cancer drug causes diabetic-like state
7. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
8. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
9. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
10. No Added Cancer Risk From Hip Replacement Materials: Study
11. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... 2014 Recently, Fadhits.com, a well-known wedding dress ... long graduation dresses to its product line. In ... loyal clients. It wants to bring more benefits for its ... offered at discounted prices, up to 72% off. , As ... working hard. Its online shop is a good place for ...
(Date:7/12/2014)... New York, NY (PRWEB) July 12, 2014 ... experienced steady growth over the past five years, buoyed ... the agricultural sector's supply management system. “Eggs are a ... a result, per capita egg consumption generally grows in ... IBISWorld Industry Analyst Will McKitterick. Furthermore, demand for new ...
(Date:7/12/2014)... Fresh off their respective performances in the 2014 World Cup, ... at Sun Life Stadium in an international friendly. The World ... stars in the world of football in Colombian and Brazilian ... some of the best talent in the world in early ... team in the world according to the Fédération Internationale de ...
(Date:7/12/2014)... report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester Resins, ... Trends & Forecast to 2018," defines and segments phthalic ... and value. The report also estimates the demand and ... anhydride is projected to grow from an estimated $6,130.55 ... a CAGR of 5.24% from 2013 to 2018. , ...
(Date:7/12/2014)... 12, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
Breaking Medicine News(10 mins):Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5
... To be joined by special guests Ringo Starr, Sheryl Crow, ... and Jim JamesTickets go on sale Monday, March 9, at ... Paul McCartney and special guests Ringo Starr, Sheryl Crow, ... Bettye LaVette, and Jim James will perform at the David ...
... CARDIFF, Calif., March 4 Rapid Fire Marketing, (Pink ... Inc., a development stage software firm utilizing the latest ... technology works off a wireless headset that responds to ... power of your own mind. The technology has ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... of BioMarin, will present a company update at the Barclays ... 2009 at 2:30 p.m. ET. Interested parties may access ... investor section of the BioMarin website, www.BMRN.com . ...
... assistant (MCA), featuring touch screen input. The MediSlate was designed ... whether that is a hospital ward, medical clinic or emergency room. ... ... TabletKiosk ®, a leader in mobile computing solutions, today announced ...
... The Johnson Institute has transferred key programs and ... Advocacy under an agreement reached last week by ... )The transfer ensures a continuation of the Johnson ... and possibility of recovery from alcoholism and dependence ...
... will be held Saturday, October 17 at , ... Chapter of the Juvenile Diabetes Research Foundation (JDRF) has announced ... Monye Connolly, will serve as the Corporate Chair for its ... The event is scheduled in Atlanta at Centennial ...
Cached Medicine News:Health News:Paul McCartney to Headline Benefit Concert for David Lynch Foundation at Radio City Music Hall on Saturday, April 4 2Health News:BioMarin to Present at the Barclays Capital Global Healthcare Conference 2Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 2Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 3Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 4Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 5Health News:Johnson Institute Transfers Key Programs and Products to Hazelden Foundation 2Health News:Juvenile Diabetes Research Foundation Names Monye Connolly Corporate Chair for its Annual Walk to Cure Diabetes 2
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation ... of directors has approved a quarterly dividend of $0.275 (27.5 ... is payable on August 1, 2014, to holders of record ... CVS Caremark is dedicated to helping people on ... company in the United States . Through ...
Breaking Medicine Technology:
... 11 Bayer HealthCare Pharmaceuticals announced today that ... U.S. Food and Drug Administration (FDA) for ciprofloxacin dry ... to Pseudomonas aeruginosa in cystic fibrosis (CF) patients. A ... Medicines Agency. Ciprofloxacin DPI is an investigational drug–device combination ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; ... recently introduced Continuum Acetabular Cup System at the ... Continuum Cup combines the best ... Technology, Metasul ® Metal-on-Metal technology, BIOLOX ® delta ...
Cached Medicine Technology:FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 2FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 3FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 4FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 5FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 6FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 7FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 8New Hip Implant Provides Personalized Fit 2New Hip Implant Provides Personalized Fit 3New Hip Implant Provides Personalized Fit 4
Used for placement of choledochoscopes, cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
... Marker directly to the biopsy site helps ... performed. ,The MICROMARK® II Tissue Marker is ... for use with the MAMMOTOME Biopsy System. ... site after a biopsy with the MAMMOTOME ...
... A biopsy with the ... an effective, minimally invasive procedure ... patient management.,Using computer-generated images to ... more accurately pinpoint and map ...
Medicine Products: